Find an Article

Filter articles

Showing 61 to 70 of 781 results

A guide for life sciences entrepreneurs

International22-12-2021Chad Shear

Small companies face the same long product cycles and upfront costs as the big players but have different IP challenges, explains Chad Shear of Fish & Richardson.

Psychedelics: from fungi and plants to patents

US30-09-2021Gretchen Temeles & Timothy Schlidt

With the significant growth of cannabinoid IP in the past few years, eyes are now on the emerging psychedelics market as the next frontier for IP protection. Gretchen Temeles of Hiller and Timothy Schlidt of Palo Santo Ventures discuss the issues.

Mexico: New hurdles for plant rights owners

Mexico23-09-2021Corina Silva

Mexico’s updated IP laws seek to avoid the patentability of plants obtained by essentially biological processes—creating issues for plant rights owners, explains Corina Silva of Uhthoff, Gómez Vega & Uhthoff.

Amendments to Chinese Patents Law for the Life Sciences

China09-09-2021Keith Haddaway and Christopher Loh

Recent changes to patent law in China sees registration, review and litigation fall in line with established international IP systems, say Venable partners Keith Haddaway and Christopher Loh.

NHS v Servier: unlawful means tort claim fails, but the long-running saga continues

UK17-08-2021Beatriz San Martin and Shishu Chen

The latest episode in the long-running dispute between the NHS and French pharmaceutical company Servier has been marked by a UK Supreme Court judgment of July 2, 2021 on Servier’s application to strike out the NHS’s unlawful means tort claim.

A new drug pricing system reform proposal in Japan

Japan17-08-2021Takanori Abe

A Japanese think tank is recommending an overhaul of Japan’s drug pricing system. Takanori Abe of Abe and Partners reports.

UK experimental use exemptions: Part 4—the SPC manufacturing and stockpiling waiver

EU10-08-2021Sophie Topham

In the final article of a four-part series, Sophie Topham of Marks & Clerk discusses the supplementary protection certificate manufacturing waiver.

UK experimental use exemptions: Part 3—the expanded exemption

UK05-08-2021Sophie Topham

In the third article of a four-part series on experimental use exemptions from infringement in the UK, Sophie Topham of Marks & Clerk considers the expansion of the original exemption.

Growing pains

International03-08-2021Joel Smith and Burkhart Goebel

Is the ‘essentially derived varieties’ concept protecting plant varieties or chilling innovation, ask Joel Smith and Burkhart Goebel of Hogan Lovells.

UK experimental use exemptions: Part 2—the Bolar exemption

UK22-07-2021Sophie Topham

In the second of a four-part series, Sophie Topham of Marks & Clerk explains the rules around the exemption for studies, tests, and trials required for generic and biosimilar medicines.

Showing 61 to 70 of 781 results